Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer

Ang, 2010, Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med, 363, 24, 10.1056/NEJMoa0912217 Bonner, 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 354, 567, 10.1056/NEJMoa053422 Morris, 2014, Interaction of radiation therapy with molecular targeted agents, J Clin Oncol, 32, 2886, 10.1200/JCO.2014.55.1366 Hayes, 2013, Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas Freudlsperger, 2011, EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy, Expert Opin Ther Targets, 15, 63, 10.1517/14728222.2011.541440 Moreira, 2017, Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies, Drugs, 77, 843, 10.1007/s40265-017-0734-0 Horn, 2015, Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma, Expert Opin Ther Targets, 19, 795, 10.1517/14728222.2015.1012157 Mohan, 2015, MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates antitumor effects in human head and neck squamous cell carcinoma, Clin Cancer Res, 21, 3946, 10.1158/1078-0432.CCR-14-3377 Rampias, 2014, RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma, Clin Cancer Res, 20, 2933, 10.1158/1078-0432.CCR-13-2721 Chen, 2015, Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature, Oncotarget, 6, 18066, 10.18632/oncotarget.3768 Lui, 2013, Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers, Cancer Discov, 3, 761, 10.1158/2159-8290.CD-13-0103 Bancroft, 2002, Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines, Int J Cancer, 99, 538, 10.1002/ijc.10398 Lattanzio, 2015, Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines, Invest New Drugs, 33, 310, 10.1007/s10637-015-0210-1 Dummer, 2017, Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 18, 435, 10.1016/S1470-2045(17)30180-8 Bendell, 2017, A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor, Br J Cancer, 116, 575, 10.1038/bjc.2017.10 Watanabe, 2016, A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors, Cancer Chemother Pharmacol, 77, 1157, 10.1007/s00280-016-3019-5 Baselga, 2017, Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 10.1016/S1470-2045(17)30376-5 Armstrong, 2017, Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer, Eur J Cancer, 10.1016/j.ejca.2017.02.030 Smyth, 2017, A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel, Invest New Drugs, 10.1007/s10637-017-0445-0 Tonlaar, 2017, Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer, Radiother Oncol, 124, 504, 10.1016/j.radonc.2017.08.001 Tonlaar, 2017, Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer, Radiother Oncol, 10.1016/j.radonc.2017.08.001 Hatzivassiliou, 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS - versus BRAF-driven cancers, Nature, 501, 232, 10.1038/nature12441 Mendoza, 2011, The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation, Trends Biochem Sci, 36, 320, 10.1016/j.tibs.2011.03.006 Fokas, 2012, NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity, Radiat Oncol, 7, 48, 10.1186/1748-717X-7-48 Park, 2017, Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer, Oncotarget, 8, 112893, 10.18632/oncotarget.22850 Prevo, 2008, Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity, Cancer Res, 68, 5915, 10.1158/0008-5472.CAN-08-0757 Toulany, 2016, Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer, Oncotarget, 7, 43746, 10.18632/oncotarget.9670 Yu, 2017, Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo, Oncotarget, 8, 68641, 10.18632/oncotarget.19817 Estrada-Bernal, 2015, MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways, Cell Cycle, 14, 3713, 10.1080/15384101.2015.1104437 Kuger, 2015, Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization, Radiat Oncol, 10, 214, 10.1186/s13014-015-0514-5 Kuger, 2013, Radiosensitization of glioblastoma cell lines by the dual PI3K and mTOR inhibitor NVP-BEZ235 depends on drug-irradiation schedule, Transl Oncol, 6, 169, 10.1593/tlo.12364 Dent, 2003, Stress and radiation-induced activation of multiple intracellular signaling pathways, Radiat Res, 159, 283, 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2 Contessa, 2002, Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells, Oncogene, 21, 4032, 10.1038/sj.onc.1205500 Dent, 1999, Mol Biol Cell, 10, 2493, 10.1091/mbc.10.8.2493 Schmidt-Ullrich, 1997, Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation, Oncogene, 15, 1191, 10.1038/sj.onc.1201275 Schmidt-Ullrich, 1996, Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells, Radiat Res, 145, 81, 10.2307/3579199 Mazumdar, 2014, A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma, Mol Cancer Ther, 13, 2738, 10.1158/1535-7163.MCT-13-1090 Wirtz, 2015, Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies, JAMA Otolaryngol Head Neck Surg, 141, 543, 10.1001/jamaoto.2015.0471 Takai, 2015, Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma, Cancer Biol Ther, 16, 325, 10.1080/15384047.2014.1002362 Emanuel, 2014, Hallway gossip between Ras and PI3K pathways, Blood, 123, 2751, 10.1182/blood-2014-03-559039 Yang, 2012, Cooperative activation of PI3K by Ras and Rho family small GTPases, Mol Cell, 47, 281, 10.1016/j.molcel.2012.05.007 Aksamitiene, 2012, Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance, Biochem Soc Trans, 40, 139, 10.1042/BST20110609 Castellano, 2011, RAS interaction with PI3K: more than just another effector pathway, Genes Cancer, 2, 261, 10.1177/1947601911408079 Kumar, 2010, Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair, Proc Natl Acad Sci U S A, 107, 7491, 10.1073/pnas.0914242107 Ibrahim, 2012, PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition, Cancer Discov, 2, 1036, 10.1158/2159-8290.CD-11-0348 Philip, 2017, Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors, BMC Cancer, 17, 638, 10.1186/s12885-017-3639-0 Kriegs, 2016, Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests, Oncotarget, 7, 45122, 10.18632/oncotarget.9161 Yaromina, 2007, Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation, Radiother Oncol, 83, 304, 10.1016/j.radonc.2007.04.020 Fokas, 2012, Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature, Cancer Res, 72, 239, 10.1158/0008-5472.CAN-11-2263 Wobb, 2015, The effects of pulsed radiation therapy on tumor oxygenation in 2 murine models of head and neck squamous cell carcinoma, Int J Radiat Oncol Biol Phys, 92, 820, 10.1016/j.ijrobp.2015.04.002